- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04191382
Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4)
June 27, 2022 updated by: Sanofi
Phase 2 Window Study of Two Dose Levels of Amcenestrant [SAR439859] (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer
Primary Objective:
To determine whether amcenestrant given at 2 different doses improved the antiproliferative activity when compared to letrozole.
Secondary Objectives:
- To assess the proportion of participants with a relative decrease from Baseline in percentage of positive tumor cells tested by immunohistochemistry greater than or equal to (>=) 50 percent (%) (Ki67 >=50%) in the three treatment arms.
- To assess estrogen receptor (ER) degradation in biopsies in participants in the three treatment arms.
- To assess safety in the three treatment arms.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Duration of the study, per participant, would include screening period of up to 14 days before randomization, treatment period of 14 days and post-treatment safety follow-up period of 30±7 days after last investigational medicinal product (IMP) intake.
Study Type
Interventional
Enrollment (Actual)
105
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, 3000
- Investigational Site Number 0560001
-
Namur, Belgium, 5000
- Investigational Site Number 0560002
-
-
-
-
-
Nantes, France, 44093
- Investigational Site Number 2500001
-
Paris, France, 75010
- Investigational Site Number 2500004
-
Saint Cloud, France, 92210
- Investigational Site Number 2500002
-
Toulouse Cedex 9, France, 31059
- Investigational Site Number 2500003
-
-
-
-
-
Meldola, Italy, 47014
- Investigational site number 3800004
-
Milano, Italy, 20132
- Investigational Site Number 3800002
-
Milano, Italy, 20141
- Investigational Site Number 3800001
-
-
-
-
-
Osaka-Shi, Japan
- Investigational Site Number 3920002
-
Sapporo-Shi, Japan
- Investigational Site Number 3920003
-
Yokohama-Shi, Japan
- Investigational Site Number 3920001
-
-
-
-
-
Hato Rey, Puerto Rico, 00917
- Investigational Site Number 8400007
-
-
-
-
-
Moscow, Russian Federation, 117186
- Investigational Site Number 6430006
-
Moscow, Russian Federation, 119991
- Investigational Site Number 6430004
-
Saint -Petersburg, Russian Federation, 197758
- Investigational Site Number 6430002
-
Saint-Petersburg, Russian Federation, 194156
- Investigational Site Number 6430003
-
St.Petersburg, Russian Federation, 195271
- Investigational Site Number 6430007
-
-
-
-
-
Barcelona, Spain, 08003
- Investigational Site Number 7240005
-
Córdoba, Spain, 14004
- Investigational Site Number 7240003
-
Madrid, Spain, 28041
- Investigational Site Number 7240001
-
Valencia / Valencia, Spain, 46010
- Investigational Site Number 7240002
-
-
-
-
-
Kharkiv, Ukraine, 61166
- Investigational Site Number 8040004
-
Uzhgorod, Ukraine, 88000
- Investigational Site Number 8040001
-
Vinnytsia, Ukraine, 21029
- Investigational Site Number 8040002
-
Zaporizhzhya, Ukraine, 69040
- Investigational Site Number 8040005
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- Investigational Site Number 8400014
-
-
California
-
Los Angeles, California, United States, 90095
- Investigational Site Number 8400010
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Investigational Site Number 8400018
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- Investigational Site Number 8400005
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Investigational Site Number 8400016
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Investigational Site Number 8400012
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion criteria :
- Histological or cytological proven diagnosis of invasive breast adenocarcinoma.
- Localized breast cancer eligible for upfront breast conservative surgery or upfront mastectomy: Stage I, Stage II or operable Stage III (excluded T4) as defined in American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition 2017.
- Postmenopausal women as defined by one of the following:
- Spontaneous cessation of menses greater than (>) 12 months.
- or who had received hormonal replacement therapy but had discontinued the treatment and had follicle stimulating hormone (FSH) level in the postmenopausal range.
- or with status post bilateral surgical oophorectomy.
- or post bilateral ovarian ablation through pelvic radiotherapy.
- Breast tumor size of at least 10 millimeters (mm) in greatest dimension measured by ultrasound.
- Primary tumor had to be positive for Estrogen Receptors (ER+) and negative for HER2 (HER2-) receptor by immunohistochemistry.
- Ki67 level of at least 15% at diagnosis from immunohistochemistry of the tumor.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion criteria:
- Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of SAR439859 or letrozole.
- Participants unable to swallow normally and to take capsules or tablets.
- Participants with known active hepatitis A, B, C infection; or hepatic cirrhosis.
- Participant with any other cancer; adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or any other cancer from which the participant had been disease free for >3 years were allowed.
- Evidence of metastatic spread by standard assessment according to local practice.
- Treatment with strong Cytochrome P450 3A (CYP3A) inducers or drugs that had the potential to inhibit uridine diphosphate glucuronosyltransferase (UGT) within 2 weeks before first study treatment administration or 5 elimination half-lives whichever was longest.
- Treatment with drugs that were sensitive substrates of P-glycoprotein (P-gp) or of breast cancer resistance protein (BCRP) within 2 weeks before first study treatment administration or 5 elimination half-lives whichever was longer.
- Use of any investigational agent within 4 weeks prior to randomization.
- Recent use of hormone replacement therapy (last dose less than or equal to [<=] 30 days prior to randomization).
- Prior anti-cancer treatment was not allowed unless it was then completed at least 1 year prior to inclusion into this trial.
- Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments).
- Inadequate hematological or renal function.
- Prothrombin time/international normalized ratio (INR) >1.5 * upper limit of normal (ULN) or outside therapeutic range if received anticoagulation that would have had affected the prothrombin time/INR.
- Any of the following abnormal liver function test results: Aspartate aminotransferase >1.5 * ULN; Alanine aminotransferase >1.5 * ULN; Total bilirubin >1.5 * ULN.
- Participants were employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.
- Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Amcenestrant 400 mg
Participants received 4 capsules of 100 milligrams (mg) of amcenestrant once daily (QD) from Day 1 to Day 14.
|
Pharmaceutical form: Capsules, Route of administration: Oral
|
Experimental: Amcenestrant 200 mg
Participants received 2 capsules of 100 mg of amcenestrant QD from Day 1 to Day 14.
|
Pharmaceutical form: Capsules, Route of administration: Oral
|
Active Comparator: Letrozole 2.5 mg
Participants received 2.5 mg of letrozole tablet QD from Day 1 to Day 14.
|
Pharmaceutical form: Tablets, Route of administration: Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Ki67 Level at Day 15
Time Frame: Baseline, Day 15
|
Tumor tissue collected through a core-cut biopsy at Baseline and Day 15 was used to determine Ki67 expression.
Ki67 expression was defined as the percentage of positive tumor cells assessed by central reading.
Ki67 percent change from Baseline for a given participant was defined as 100*(Ki67pre - Ki67post) / Ki67pre, where Ki67pre and Ki67post were pre-treatment and post-treatment Ki67 value of the participant.
Adjusted geometric least square (LS) means and 95 percentage (%) confidence interval (CI) for the percent change were obtained from analysis of covariance (ANCOVA) model of the log proportional change i.e., log (Ki67post/ki67pre) with treatment and log-Ki67pre as fixed effect and converted by antilog transformation.
|
Baseline, Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Percent Change From Baseline in Ki67 Greater Than or Equal to (>=) 50 Percent at Day 15
Time Frame: Baseline, Day 15
|
Tumor tissue collected through a core-cut biopsy at Baseline and Day 15 was used to determine Ki67 expression.
Ki67 expression was defined as the percentage of positive tumor cells assessed by central reading.
Ki67 percent change from Baseline for a given participant was defined as 100*(Ki67pre - Ki67post) / Ki67pre, where Ki67pre and Ki67post were pre-treatment and post-treatment Ki67 value of the participant.
|
Baseline, Day 15
|
Change From Baseline in Estrogen Receptor (ER) Expression as Measured by H-Score at Day 15
Time Frame: Baseline, Day 15
|
Change from Baseline in ER expression was measured by H-Score.
The H-score was calculated as the sum of the percent of cells staining positive (0 to 100) multiplied staining intensity level from 0 to 3 (0=none, 1=low, 2=moderate, 3=high).
Total ER expression H-score ranged from 0 to 300, where higher score indicated stronger ER expression.
Change from Baseline in H-Score equals H-scorepost minus H-scorepre; where H-scorepost and H-scorepre denoted post-treatment and pre-treatment H-scores, respectively.
LS-means and 95% CI were obtained from an ANCOVA model for change from baseline with treatment and baseline as fixed effect.
|
Baseline, Day 15
|
Number of Participants With Abnormalities: Hematological Parameters
Time Frame: From first dose of study drug up to Day 14
|
Hematology parameters covered by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and included: Hemoglobin, Lymphocyte, Neutrophils, Leukocytes (white blood cells), Anemia, Platelets, Eosinophils, and international normalized ratio (INR).
An NCI-CTCAE Grades 1 to 5 were described as: Grade 1-Mild; asymptomatic/mild symptoms; Grade 2-Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental daily activities.
Grade 3-Severe/medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4-Life-threatening consequences; Grade 5-Death.
Data for 'All Grades' were reported in this outcome measure.
|
From first dose of study drug up to Day 14
|
Number of Participants With Abnormalities: Clinical Chemistry
Time Frame: From first dose of study drug up to Day 14
|
Clinical chemistry laboratory parameters covered by NCI-CTCAE and included: Glucose, Potassium, Sodium, Creatinine.
An NCI-CTCAE Grades 1 to 5 were described as: Grade 1-Mild; asymptomatic or mild symptoms; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental daily activities; Grade 3-Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4-Life-threatening consequences; Grade 5-Death.
Data for 'All Grades' were reported in this outcome measure.
|
From first dose of study drug up to Day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 4, 2020
Primary Completion (Actual)
April 30, 2021
Study Completion (Actual)
May 28, 2021
Study Registration Dates
First Submitted
December 5, 2019
First Submitted That Met QC Criteria
December 5, 2019
First Posted (Actual)
December 9, 2019
Study Record Updates
Last Update Posted (Actual)
June 29, 2022
Last Update Submitted That Met QC Criteria
June 27, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
Other Study ID Numbers
- ACT16106
- 2019-002015-26 (EudraCT Number)
- U1111-1228-9473 (Other Identifier: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.
Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
Clinical Trials on Amcenestrant (SAR439859)
-
SanofiCompletedBreast Cancer | Healthy VolunteersUnited Kingdom
-
SanofiActive, not recruiting
-
SanofiTerminatedHepatic Function AbnormalKorea, Republic of, Germany
-
SanofiTerminatedBreast CancerUnited States, Russian Federation, Italy, Australia, Belgium, France, Japan, Ukraine, Netherlands, Argentina, Canada, Portugal, Spain, Austria, Brazil, Bulgaria, Chile, China, Czechia, Finland, Georgia, Germany, Hungary, Korea, Republic... and more
-
SanofiActive, not recruitingBreast CancerCzechia, Belgium, Spain, United States, France, Canada, Italy, Poland, Portugal, United Kingdom
-
SanofiEuropean Organisation for Research and Treatment of Cancer - EORTC; Alliance... and other collaboratorsTerminated
-
QuantumLeap Healthcare CollaborativeRecruitingBreast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast CancerUnited States
-
SanofiActive, not recruitingBreast Cancer MetastaticKorea, Republic of, Belgium, Taiwan, China, France, United States, Argentina, Australia, Brazil, Canada, Czechia, Greece, Israel, Italy, Japan, Latvia, Mexico, Poland, Puerto Rico, Russian Federation, Spain, Turkey, Ukraine